Group develops predictor system for poorer diagnosis HL patients

A novel scoring system has been developed for pediatric Hodgkin's lymphoma patients that reveals four basic factors that contribute to a worse event-free survival following treatment.

The system is known as CHIPS (Childhood Hodgkin International Prognostic Score), and according to Dr. Cindy Schwartz and her colleagues at the Children's Oncology Group,the four factors are:

-- Stage IV disease
-- Large mediastinal adenopathy
-- Albumin level of less than 3.5 g/dL
-- Fever

Giving one point for each adverse predictors, researchers concluded that the event-free survival rate in Hodgkin's patients was the following, according to the accompanying CHIPS score:

-- CHIPS score 0-1: 90%
-- CHIPS score 2: 78%
-- CHIPS score 3: 62%

Researchers enrolled only intermediate-disease patients, meaning they were unable to determine an event-free survival rate for a CHIPS score of 4.

In conclusion, they determined that 22% of an intermediate-risk patient population will likely experience an event-free survival rate of less than 80%. This knowledge will allow doctors to have a much better idea of who will and who will not respond to initial therapy, and make the appropriate treatment changes.

In 2009, Schwartz and the Children's Oncology Group developed the chemotherapy regimen ABVE-PC for pediatric Hodgkin's patients.

Source: Oncology Report

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap